Biosimilar Pathway
Cosentyx (secukinumab) is a biologic, not a small-molecule drug. Biologics are not listed in the FDA Orange Book and do not face conventional “generic” competition. Instead, follow-on competitors called biosimilars can be approved through the FDA’s BPCIA pathway, typically after the reference product’s 12-year exclusivity period and the resolution of any patent litigation.
For the current biosimilar approvals and exclusivity status of Cosentyx, see the authoritative FDA Purple Book listing for secukinumab.
Related Drug Patent Expirations
6 patents · earliest expires 2027 · Novartis AG
0 patents · Genentech Inc.
9 patents · earliest expires 2033 · Gilead Sciences Inc.
0 patents · Janssen Biotech Inc.
0 patents · Regeneron Pharmaceuticals Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
The Cosentyx record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Cosentyx sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Cosentyx is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.